(2)
The European Patent Office has granted SSH Communications Security Corporation a further patent for PrivX technology
Helsinki, Finland - January 20, 2021 - The European Patent Office (EPO) has granted SSH patent number EP 3495976 on the use of virtual smart cards in temporary certificate-based passwordless access such as the SSH PrivX technology.
Passwords are a hassle to use, and they present significant security risks for users and organizations of all sizes, with an average of one in every 250 corporate accounts compromised each month. The World Economic Forum (WEF) estimates that cybercrime costs the global economy $2.9 million every minute, with roughly 80 percent of those attacks directed at passwords. Furthermore, password management is very costly: according to the analyst firm Gartner, up to 20 to 50 percent of all help desk calls are for password resets.
Japan s Nidec Corp said on Wednesday it had filed a patent infringement lawsuit against Seagate Technology LLC and its affiliates, accusing it of using Nidec hard disk drive motor designs without. | January 20, 2021
(1)
Patent protects Company s lead clinical asset FS118 throughout Europe
CAMBRIDGE, United Kingdom and CAMBRIDGE, Mass., Jan. 20, 2021 (GLOBE NEWSWIRE) F-star Therapeutics, Inc. (NASDAQ: FSTX), a clinical-stage biopharmaceutical company dedicated to developing next generation immunotherapies to transform the lives of patients with cancer, today announces the European Patent Office (EPO) has granted a patent with claims protecting the composition of matter of F-star s FS118 molecule throughout Europe. The expiry date of the patent, not including any potential extensions to the standard 20-year term of protection, is expected to be June 2037.
According to the EPO s decision, grant of European Patent number 3472207 will take effect on January 20, 2021. The decision to grant this patent follows the EPO s December 10, 2020 notice of intent to issue the patent, which was not challenged by any third party.
Illumina, Inc.: Illumina Wins Patent Infringement Suit against BGI in the UK
Illumina, Inc. (NASDAQ: ILMN) today announced that the High Court of Justice, Chancery Division, Patents Court, issued a judgment in its favor in the patent infringement suit filed against the BGI Companies, MGI Tech Co. Ltd; Latvia MGI SIA; MGI International Sales Co., Ltd; and BGI Complete Genomics Hong Kong Co., Ltd.
The Court found that four of the five asserted patents were valid and infringed by BGI. The Court ruled that BGI s StandardMPS and CoolMPS systems infringe EP 1 530 537 B1, EP 3 002 289 B1, and EP 3 587 433 B1, and that StandardMPS also infringes EP 2 021 415 B1. These patents cover different aspects of Illumina s proprietary sequencing-by-synthesis chemistry, including its azidomethyl reversible terminator and labelled nucleotides.